Verastem, Inc. (VSTM) Company Overview

What does Verastem do?

Verastem, Inc., branded as Verastem Oncology, is a commercial-stage biopharmaceutical company listed on the Nasdaq Capital Market under VSTM. Its focus is unusually narrow: medicines for cancers driven by the RAS/MAPK signaling pathway. The company moved from development-stage biotechnology to commercial oncology in May 2025, when the U.S. Food and Drug Administration granted accelerated approval to AVMAPKI FAKZYNJA CO-PACK for adults with KRAS-mutated recurrent low-grade serous ovarian cancer, or LGSOC, after prior systemic therapy. The approval created the first treatment specifically authorized for that population and transformed Verastem from a pipeline story into a product-launch story.

Product and company identity

The official investor profile describes a company built around small-molecule inhibitors that interrupt cancer-cell survival, tumor growth, and resistance. Its identity is one commercial combination plus trials extending the same pathway expertise into ovarian, pancreatic, lung, and colorectal cancers.

How does Verastem make money?

Verastem currently earns revenue by selling AVMAPKI FAKZYNJA CO-PACK through a limited network of specialty pharmacies and specialty distributors. Revenue is recognized on delivery and reported net of discounts, chargebacks, rebates, returns, copay assistance, and other support programs. Payer mix, channel mix, reimbursement terms, and reserves can therefore move net sales even when prescriptions are stable.

The revenue and cash-conversion chain

One commercial asset, several option-like programs

The commercial product also carries royalty and milestone obligations. Avutometinib was licensed from Chugai, with double-digit royalties on net sales, while defactinib is subject to a Pfizer license. The GenFleet collaboration can also require development, commercial, sales, and option payments; the 2025 Form 10-K disclosed up to $622.0 million of potential milestones plus mid- to high-single-digit royalties. These obligations reduce the economics versus a fully owned drug.

What does the first quarter of 2026 reveal about launch economics?

The first-quarter 2026 results show a launch gaining scale but not yet funding the whole enterprise. Revenue of $18.7 million exceeded fourth-quarter 2025 product revenue of $17.5 million and equaled about 61% of full-year 2025 product revenue. Yet operating expenses remained far above gross profit because Verastem was simultaneously building commercial infrastructure and accelerating several oncology trials.

Launch revenue progressed across four reported periods

Margin math and operating burden

The detailed March 2026 Form 10-Q also reported $73.1 million of long-term debt, $146.0 million of total liabilities, $81.8 million of stockholders’ equity, and 87.8 million common shares outstanding at quarter-end. Those figures make dilution, financing access, and trial spending as important as sales growth.

Which turning points created today’s Verastem?

Verastem’s history is best understood as repeated portfolio concentration. It commercialized and exited COPIKTRA, acquired a differentiated RAF/MEK inhibitor, added a FAK combination strategy, and then direct KRAS G12D inhibition. Each pivot reduced complexity while increasing dependence on fewer high-value programs.

From founding to a focused RAS/MAPK company

1. 2010
   Incorporated in Delaware. The early-stage structure established Verastem as a research-led oncology company dependent on external capital.
2. 2020
   Licensed avutometinib from Chugai in January, creating the RAF/MEK foundation that later became AVMAPKI. In September, Verastem sold COPIKTRA assets to Secura for $70.0 million upfront plus potential milestones and royalties, shifting resources away from the earlier franchise.
3. 2022
   PanCAN awarded up to $3.8 million for the RAMP 205 pancreatic-cancer program, validating the combination concept and supporting trial execution.
4. 2023
   RAMP 301 began as the confirmatory Phase 3 LGSOC study. Verastem also entered the GenFleet option collaboration and selected VS-7375 as its lead direct-KRAS program.
5. 2025
   AVMAPKI FAKZYNJA received accelerated U.S. approval on May 8 and became commercially available within one week. Verastem also exercised its VS-7375 option and started the U.S. Phase 1/2 program.
6. 2026
   The company initiated three registration-directed TARGET-D Phase 2 trials and reported new RAMP 205 and VS-7375 data, making pipeline execution the next determinant of strategic value.

Why are AVMAPKI FAKZYNJA and VS-7375 strategically important?

The LGSOC franchise is both product and proof of mechanism

AVMAPKI inhibits MEK and blocks compensatory RAF-driven MEK reactivation; FAKZYNJA inhibits focal adhesion kinase, a resistance pathway activated when RAF/MEK signaling is blocked. The combination targets tumor growth and adaptive resistance together. Its May 2025 accelerated approval rests on response rate and duration, so continued approval depends on confirmed clinical benefit. RAMP 301 enrolled 270 targeted patients and added 29 after an independent monitoring recommendation; a primary-endpoint readout is expected in mid-2027. Success could support full approval and a broader recurrent-LGSOC label regardless of KRAS status.

VS-7375 expands the addressable biology

VS-7375 is designed to bind both active and inactive states of KRAS G12D. That dual ON/OFF thesis is intended to produce deeper pathway suppression than compounds that bind only one state. The opportunity is broader than LGSOC: Verastem estimates KRAS G12D represents 26% of KRAS mutations and appears in roughly 40% of pancreatic, 15% of colorectal, and 5% of non-small cell lung cancers. The company’s June 2026 TARGET-D update reported activity at 400 mg, 600 mg, and 900 mg once daily, with dose escalation continuing at 1,200 mg.

The June 2026 RAMP 205 update is encouraging but preliminary. With 9.8 months median follow-up, 83% of patients experienced tumor shrinkage and nine remained on treatment. For valuation, these are probability-weighting inputs, not approved-product cash flows.

Who competes with Verastem, and what is the moat?

Competition is program-specific, not company-wide

In recurrent LGSOC, Verastem competes with physician-selected chemotherapy, hormonal therapy, off-label targeted approaches, and emerging clinical programs. In KRAS G12D, it faces better-capitalized companies pursuing mutation-specific inhibitors, pan-RAS agents, combinations, and alternative mechanisms. The 2025 Form 10-K names companies including Novartis, Pfizer, Quanta Therapeutics, Ranok Therapeutics, Revolution Medicines, and others. Larger rivals can recruit trial sites faster, manufacture at scale, and absorb development setbacks more easily.

The practical moat is an integrated bundle

How strong are liquidity, cash flow, and capital allocation?

Cash is meaningful, but the burn rate is the constraint

At March 31, 2026, Verastem held $165.6 million of cash and equivalents plus $16.1 million of short-term investments, or $181.7 million total. Q1 operating cash use was $52.1 million, investment purchases used $16.0 million, and financing supplied $28.7 million, mainly from warrant exercises. Long-term debt was $73.1 million and long-term vendor financing $3.8 million. The 10-Q said TARGET-D Phase 2 commitments raised projected R&D spending and created substantial doubt about continued operations without more capital or sufficient commercial revenue.

Capital allocation is dominated by launch and pipeline expansion

For a DCF, net loss is not a sufficient free-cash-flow proxy. The useful bridge is operating cash flow less required investment uses, while financing proceeds remain separate. Fixed-asset capex is small, but clinical manufacturing, milestones, working capital, and trial commitments are economic reinvestment. The 2025 Form 10-K reported $30.9 million of product revenue, $201.0 million of total operating expenses, a $209.5 million net loss, $205.0 million of year-end cash, and an accumulated deficit of $1.165 billion.

Who owns VSTM, and how is the company governed?

The investor base is concentrated among specialist institutions

Verastem has one common share class with one vote per share. The 2026 proxy reported 87,842,899 shares outstanding on March 24, 2026. RTW-related entities and Deep Track-related entities each reported 9.99% beneficial ownership after applying warrant conversion limitations; BlackRock-related entities held 5.41%, and Balyasny-related entities held 5.33%. Directors and executive officers as a group held 1.94%. This structure gives healthcare-focused institutions meaningful influence but does not create founder or dual-class control.

Board oversight matches a commercializing biotech

The board maintains Audit, Compensation, Nominating and Corporate Governance, Research and Development, and Commercialization Committees. Most committee members are independent, with designated scientific and commercial expertise. Daniel Paterson serves as president and chief executive officer, while an independent lead director supports board deliberation. The 2026 proxy statement is especially relevant because equity awards, dilution, commercial execution, and pipeline milestones are tightly linked in a company that still depends on external financing.

What opportunities and risks could change the story?

The opportunity set is concentrated but asymmetric

The risk map links clinical events to financial lines

The official approval announcement makes the central trade-off clear: Verastem owns a first-in-disease commercial position, but the indication is accelerated, narrow, and linked to a confirmatory trial. The company’s opportunity is therefore not simply “sell more of the first product.” It is to use the launch, mechanism, and specialist network to build a broader franchise before cash constraints or competition narrow the window.

What matters most in a Verastem valuation and final takeaway?

DCF value comes from separate probability-weighted engines

The key assumptions are launch penetration, RAMP 301 success, VS-7375 response durability, the cost of three registration-directed studies, and dilution before self-funding scale. A terminal-growth DCF is weak if it treats every pipeline asset as certain. A better approach values the approved LGSOC business, a possible broader label, RAMP 205, and each TARGET-D indication as separate risk-adjusted streams, then adjusts for debt and excess cash.

The company-specific conclusion